

Tecan announces change in Management Board

- **Frederic Vanderhaegen is leaving the company**
- **Search for a successor has been initiated**

Männedorf, Switzerland, May 8, 2012 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that Frederic Vanderhaegen, Head of Division Life Sciences Business and member of the Group Management Board, decided to leave the company to pursue other career opportunities at Beckman Coulter Life Sciences, part of Danaher Corporation. He will leave Tecan by no later than the end of November 2012. The search for a successor is initiated.

Tecan's Board of Directors and CEO regret Mr Vanderhaegen's decision. They would like to thank him warmly for his valuable contribution to the development of Tecan and wish him all the best for the future.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).

For further information:

Tecan Group

Martin Brändle

Head of Corporate Communications & Investor Relations

Tel. +41 (0) 44 922 84 30

Fax +41 (0) 44 922 88 89

investor@tecan.com

www.tecan.com